Chief Regulatory Officer Wentworth Kerry purchased 50,000 shares at blended average $1.79 totaling $89,740.00; stock is -53.3% from 52-week high and company is unprofitable with -$53.2M net income.
Wentworth Kerry, Chief Regulatory Officer at Nuvation Bio, executed two separate purchases totaling 50,000 shares for $89,740.00 on 2025-06-16, establishing a position from zero prior holdings. The stock is trading at $1.79, down 53.3% from its 52-week high of $3.83 and down 22.2% over the past 30 days, while the company reported negative net income of $-53.2M on quarterly revenue of $3.1M. The filing occurs within a cluster period in which 4 other insiders also bought within the past 14 days, indicating coordinated insider buying activity during a period of significant stock price deterioration and operational losses. This pattern merits observation given the insider's regulatory function and the concurrent buying momentum from peer executives.